About Us
Founded in 2018, Rinri Therapeutics Ltd. is a therapeutic discovery and development company working in the field of hearing loss supported by Boehringer Ingelheim Venture Fund and UCB Ventures, BioCity and The University of Sheffield.
Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
The Company has a team of experienced management, strong academic pedigree and excellent potential for clinical development.
Latest News
Rinri Therapeutics accelerates first regenerative cell therapy for hearing loss towards clinic with key senior hires and award of Innovation Passport
Rinri Therapeutics accelerates first regenerative cell therapy for hearing loss towards clinic with key senior hires and award of Innovation Passport The company's lead therapeutic candidate, Rincell-1, receives innovative Read more
Rinri Therapeutics Secures Innovate UK Funding Grant for £3.2m Project to Advance its Novel Cell-Based Therapy to Restore Hearing Loss
Rinri Therapeutics Secures Innovate UK Funding Grant for £3.2m Project to Advance its Novel Cell-Based Therapy to Restore Hearing Loss Sheffield, UK, 13th May 2021: Rinri Therapeutics Read more
Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss
Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss Sheffield, UK, 20 April 2021: Read more
Rinri Therapeutics Appoints Experienced Life Science Executive Nick Higgins as Chairman
Rinri Therapeutics Appoints Experienced Life Science Executive Nick Higgins as Chairman Extensive private and public company corporate development track record Significant expertise in cell and gene therapy Read more